These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 36081566)
1. Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. Ma D; Ma Y; Ma Y; Liu J; Gu Y; Liu N; Xiang C; Liu H; Sang W Front Oncol; 2022; 12():941347. PubMed ID: 36081566 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study. Sang W; Ma Y; Wang X; Ma Y; Shen Z; Gu W; Wang F; Ye J; Zhang C; Miao Y; Xu C; Liu Q; Li B; Tu J; Wang C; Shi Y; Sun S; Yan D; Song X; Sun C; Shao Y; Xu L; Li Z; Ma D; Xu K; Young KH; Liu H Am J Surg Pathol; 2022 Nov; 46(11):1533-1544. PubMed ID: 36006771 [TBL] [Abstract][Full Text] [Related]
3. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Xu-Monette ZY; Wei L; Fang X; Au Q; Nunns H; Nagy M; Tzankov A; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Sun X; Han X; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Albitar M; You H; Young KH Clin Cancer Res; 2022 Mar; 28(5):972-983. PubMed ID: 34980601 [TBL] [Abstract][Full Text] [Related]
4. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379 [TBL] [Abstract][Full Text] [Related]
5. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics. Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996 [TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G; J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305 [TBL] [Abstract][Full Text] [Related]
7. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469 [TBL] [Abstract][Full Text] [Related]
8. Genetic profiling of Ennishi D; Mottok A; Ben-Neriah S; Shulha HP; Farinha P; Chan FC; Meissner B; Boyle M; Hother C; Kridel R; Lai D; Saberi S; Bashashati A; Shah SP; Morin RD; Marra MA; Savage KJ; Sehn LH; Steidl C; Connors JM; Gascoyne RD; Scott DW Blood; 2017 May; 129(20):2760-2770. PubMed ID: 28351934 [TBL] [Abstract][Full Text] [Related]
9. Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature. Lee J; Hue SS; Ko SQ; Tan SY; Liu X; Girard LP; Chan EHL; De Mel S; Jeyasekharan A; Chee YL; Koh LP; Poon LM Expert Rev Hematol; 2019 Dec; 12(12):1095-1105. PubMed ID: 31592693 [No Abstract] [Full Text] [Related]
10. Clinical Significance of Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907 [No Abstract] [Full Text] [Related]
11. Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes. Zhou Y; Xu Z; Lin W; Duan Y; Lu C; Liu W; Su W; Yan Y; Liu H; Liu L; Zhong M; Zhou J; Zhu H Front Oncol; 2019; 9():683. PubMed ID: 31403034 [TBL] [Abstract][Full Text] [Related]
12. Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia. Phang KC; Akhter A; Tizen NMS; Rahman FA; Zahratul Azma R; Elyamany G; Shabani-Rad MT; Masir N; Mansoor A J Clin Pathol; 2018 Mar; 71(3):215-220. PubMed ID: 28775174 [TBL] [Abstract][Full Text] [Related]
13. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma. Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231 [TBL] [Abstract][Full Text] [Related]
15. De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients. Fan Y; Binshen O; Zhang Z; Yi H; Zhang W; Liu Q; Liu Y; Dong L; Wang C Ann Diagn Pathol; 2022 Jun; 58():151886. PubMed ID: 35255429 [TBL] [Abstract][Full Text] [Related]
16. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes. Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457 [TBL] [Abstract][Full Text] [Related]
17. CD5+ diffuse large B-cell lymphoma has heterogeneous clinical features and poor prognosis: a single-center retrospective study in China. Yin T; Qi L; Zhou Y; Kong F; Wang S; Yu M; Li F J Int Med Res; 2022 Sep; 50(9):3000605221110075. PubMed ID: 36112929 [TBL] [Abstract][Full Text] [Related]
18. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group. Ma S; Zhang B; Lu T; Li D; Li T; Shen Z; He C; Wang Y; Li B; Zhang H; Gu W; Wang C; Ye J; Zhu T; Miao Y; Wang L; Huang S; Liu Q; Sang W; Cancer; 2022 Oct; 128(19):3487-3494. PubMed ID: 35932292 [TBL] [Abstract][Full Text] [Related]
19. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242 [TBL] [Abstract][Full Text] [Related]
20. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]